Bethesda, MD (PRWEB) February 18, 2015
A new study published in the journal Nature found that genetics plays a bigger role in the development of obesity than was previously thought. Researchers from the University of Michigan unveiled the results of a genome-wide association study looking at body mass index (BMI), a common measure of obesity, in close to 400,000 individuals (Nature, 518:197-206;February 11, 2015).
This new research finds that as much as 21% of BMI variation can be accounted for by genetics. There are about 100 locations across the genome that plays roles in various obesity traits, double than what was previously thought.
This research may help determine who is at risk of developing diseases associated with obesity and may lend insight into future treatment, says Elaine Trujillo, nutritionist and author of The Calories In Calories Out Cookbook. We have known that one size does not fit all when it comes to weight gain, development of risk factors and even obesity treatment. Now we have more research to support that notion, Trujillo adds.
According to Caroline Apovian, Professor of Medicine and Pediatrics and the Director of the Nutrition and Weight Management Center, Boston Medical Center, Boston University, For those of us treating obesity, this is exciting news because particular genes and pathways affecting BMI have been implicated that respond to changes in eating behavior. Once we can figure out which of these genes are implicated in each patient, we can tailor the treatment of their obesity based on their particular genetic profile. For example, one of the pathways implicated in this paper is one that is the proposed mechanism of action of the combination of drugs recently approved by the US Food and Drug Administration for treatment of obesity topiramate/phentermine. Based on genetic profiles, we may be able to predict which patients will be successful at weight loss with this particular drug combination (topiramate/phentermine) as opposed to another treatment if they have this pathway variation. Also, we may be able to predict who will do well with bariatric surgery in the future.
In a companion paper on waist-to-hip circumference ratios, 49 sites in the genome were identified (Nature 518:187-186; February 12, 2015). The waist-to-hip ratio and waist circumference alone are used to determine fat distribution and abdominal fatness and is a marker for developing diseases associated with obesity. Men who have waist circumferences greater than 40 inches and women who have waist circumferences greater than 35 inches are at higher risk of diabetes, dyslipidemia, hypertension, and cardio-vascular disease.
Much more research is needed to determine how the genetic variations in individuals lead to weight gain in some and not in others. Some of the genes involved in obesity may be related to other diseases, this research is a step in uncovering the biological basis to a whole host of metabolic diseases. Although genetic background may be a useful tool in the future for developing personalized diets for weight loss and health, those who are already living in calorie balance and engaging in regular physical activity will have the basis for a foundation for healthy living.
CATHERINE JONES is the award-winning author or coauthor of numerous cookbooks including The Calories In, Calories Out Cookbook, Eating for Pregnancy, and Eating for Lower Cholesterol. She is the co-founder of the nonprofit Share Your Calories, an app developer, blogger, and a freelance journalist. ELAINE TRUJILLO, MS, RDN, is a nutritionist who has years of experience promoting nutrition and health and has written numerous scientific journal articles, chapters and textbooks.
New Delhi (PRWEB) September 21, 2014
A 25 year old IT professional was struck with Hodgkin s disease which is one of the most curable cancers. He was treated with standard chemotherapy and the disease went away only to reappear a few months later. This time he received local radiation and Autologous Bone Marrow Transplantation (BMT). However, the response was short lived and the cancer sprung its ugly head within 6 months.
The young man and his distraught family went from one centre to another. Various forms of chemotherapy and a new drug called Brentuximab were suggested to him by the experts. However, the drug Brentuximab had to be imported and each cycle of treatment would have costed 5 lakhs. Some had suggested an Allogeneic BMT but his only brother was fully mismatched with him and this option was no longer a consideration.
Dr Suparno Chakrabarti and Dr Sarita Jaiswal had been running a HAPLOIDENTICAL BMT PROGRAM in the country for 3 years and the patient and his father came to them at Dharamshila BMT Centre (http://bmthospitalindia.com) despite all the other experts in the country discouraging them to go for such an option. At the outset, the patient was given standard chemotherapy which showed an initial response, but as it had happened so many times before, the cancer bounced back. The patients parents were half matched with him as expected, but the team at Dharamshila realised that just doing the BMT is not going to help the young man. They identified a unique population of white blood cells in the father, but not in the mother which could kill the tumour cells without causing any adverse reaction in the patient. They are called KIR ligand mismatched NK cells. These cells were analysed and were found very effective in killing tumour cells in the test tube. Dr Sarita Jaiswal had been trained in transplants involving such cell manipulations at Italy and USA. The patients body could not have received any further intensive chemotherapy. They sought help from Dr Kanika Sharma to administer a small dose of radiation to the entire body keeping in mind that he has already received a very large dose of radiation to his heart, lungs and neck. With this tiny dose of radiation and some immuno suppressive drugs the patient was infused half matched cells from his father and 7 days later his fathers white cells were collected and the special cells were separated and infused to the patient.
The stem cells from the father started growing in the patient after 2 weeks and he remained free of all bacterial and viral infections since then. The blood and bone marrow of the patient were regularly analysed and it showed that the cells from the father which were supposed to be killing the tumour without causing any reaction in the patient, were growing in number. Sixty days after the BMT, a PET scan was done to see the state of the cancer. To everyones joy and surprise, it had disappeared completely.
Few such cases have been reported worldwide and this is the first time Indian doctors have used innovation, science and technology to cure such a refractory cancer. Dr Sarita Jaiswal had seen some very impressive results with Haploidentical BMT using cell manipulation, but to replicate the procedure in its entirety would cost 40 lakhs at least. Hence, Dr Sarita innovated this unique way of carrying out the Half matched BMT at a low cost and administer selective cells at the right time which shall help in hitting the tumour as well as fighting infections.
Several such Haploidentical BMT using this unique and innovative technology are being carried out by Dr Sarita Jaiswal at Dharamshila BMT Centre. Dr Sarita says that it is not just about giving the cells but understanding the science behind it and applying it in the right context in the correct way. Dr Suversha Khanna, who had long dreamt of a BMT unit at Dharamshila Hospital expressed her satisfaction at the optimum utilisation of the world class infrastructure so painstakingly erected in the hospital, 20 years after its inception. She said that that there is little point in having yet another BMT centre, if its not going to make a difference to the majority of the suffering patients. Today, with the infrastructure and the expertise of the BMT team, ably supported by Radiation Oncologists, its possible that every patient who needs a BMT can have one from a Half matched (HAPLOIDENTICAL) Parents, Siblings or Children and with the right choice of donor can even get cured of otherwise refractory blood or lymph gland cancers. Dr Suparno Chakrabarti who had started such transplants for the first time in India says that the glass is always half full.
ABOUT DHARAMSHILA HOSPITAL AND RESEARCH CENTRE
Passion for Excellence in Cancer Care
A group of concerned relatives and friends of cancer patients felt the need to provide complete cancer treatment under one roof. They felt it was their Dharma (duty) to provide to cancer patients what was not available to their near and dear ones, when they were suffering from cancer. They laid the Shila (foundation) of their duty by registering a NGO, Dharamshila Cancer Foundation And Research Centre (DCFRC) on 19 April, 1990.
DCFRC Commissioned the first phase of the Dharamshila Cancer Hospital And Research Centre (DCHRC) with 100 beds in 1994 and expanded to 300 beds in 2006, with the sole objective of making cancer treatment available, accessible and affordable.
Being totally focused on cancer for more than two decades, Dharamshila is continuously adding world class cutting edge technologies for early diagnosis and cancer treatment.
Dharamshila Hospital is the most trusted cancer hospital for patients from all over India and neighbouring countries for its policy of avoiding unnecessary procedures/hospitalization and transparent billing. Dharamshila hospital has won the goodwill of thousands of Patients who are enjoying cancer free life.
Highly qualified skilled and experienced teams of organ specific cancer specialists practice evidence based medicine and follow international treatment guidelines to achieve best treatment outcomes.
Being sensitive to the physical, medical, emotional and financial needs of patients, Dharamshila strives to serve patients with love, devotion, compassion, commitment and positive attitude.
High quality standards of treatment, complete patient safety and satisfaction, improving cure rates and adding quality to life will always remain our hallmark.
Lake Wales Police Sergeant Arrested for Unlawful Sexual Activity With Minor
Aaron Woodford Barnes 37 has been charged with four counts of Sexual Activity with Certain Minors and one count of Contributing to the Delinquency of a Minor. The investigation began mid morning yesterday after Lake Wales Police were informed by a …
Read more on The Daily Ridge
REGIONAL NEWS: Gloucestershire man jailed for having sexual activity with a …
An illegal immigrant has been jailed for six years after abducting and having sexual activity with a 13-year-old girl. Davinder Singh, 30, began seeing the youngster, who cannot be named for legal reasons, claiming he thought she was 18. The …
Read more on Bath Chronicle
When can you resume having sex after a heart attack?
Sex also requires this kind individualized counseling. New research shows that patients want to talk about sexual activity with their doctors, but that all too often that conversation never takes place. A recent study conducted in 127 hospitals in the …
Read more on Washington Post
Health minister in eight-week Men's Health challenge to prove busy people have …
Daniel Masoliver, features editor at Men's Health, added: 'We hope that this feature will prove that no-one is too busy to take care of their physical health, and that Dr Poulter and the other Members of Parliament involved will inspire readers to make …
Read more on Pulse
Men's health, wellness seminar slated Feb. 21 in Donaldsonville
St. Catherine of Sienna Catholic Church, Tamiko Francis Garrison, Peoples Health, United Healthcare, Amerihealth Caritas Louisiana and Louisiana Healthcare Connections will host a men's health and wellness seminar from 7:30 a.m. to 1 p.m. Feb. 21 at …
Read more on The Advocate
Albany, NewYork (PRWEB) February 12, 2015
ResearchMoz has announced the addition of the Iron Deficiency Anemia Global Clinical Trials Review, H2, 2014 report to their offering. The 105-page publication is an attempt to help clients understand the structure, dynamics, scope, elements, and performance of an iron deficiency anemia clinical trial.
Complete Report With TOC @ http://www.researchmoz.us/iron-deficiency-anemia-global-clinical-trials-review-h2-2014-report.html
Iron deficiency anemia has two main causes: loss of iron from bleeding and insufficient dietary intake and absorption of iron. Iron deficiency is the reason behind nearly half of all anemia cases around the world; women are more susceptible to anemia than men.
Doctors state that iron deficiency anemia can be easily treated, depending upon the cause and severity of the condition. Researchers around the globe have been studying the causes and treatment options for iron deficiency anemia and clinical trials in various phases are being conducted for this purpose. These clinical trials also test new and innovative ways of diagnosing anemia among varied demographics. Some of the clinical trials for iron deficiency anemia are designed to find ways of preventing iron deficiency in infants while others are targeted towards finding the causes of unexplained anemia among older population classes. Clinical trials allow pharmaceutical companies and healthcare providers to test the safety of new treatment options on humans before they are made commercially available.
The review of the various iron deficiency anemia clinical trials being conducted across the globe covers key regions such as Europe, Asia-Pacific, the Middle East and Africa, North America, and Central and South America. The top five countries in each of these regions are identified and their contribution to iron deficiency anemia clinical trials is evaluated. Clinical trials being carried out in G7 countries (France, Canada, Germany, Italy, the United States, the United Kingdom, and Japan) and E7 countries (India, China, Brazil, Russia, Mexico, Turkey, and Indonesia) are studied by phase and status. Unaccomplished trials in these countries are also studied.
There are numerous companies participating in iron deficiency anemia therapeutic clinical trials. These include pharmaceutical companies such as Shield Therapeutics, Actavis plc, Pharmacosmos A/S, AMAG Pharmaceuticals, Inc., Galenica Ltd., Daiichi Sankyo Company, Limited, and Rockwell Medical, Inc., and laboratories such as Keryx Biopharmaceuticals, Inc. and Pierre Fabre SA. A comprehensive overview of the company as well as the anemia clinical trial conducted or funded by these pharmaceutical companies has been provided in the research report.
Request A Sample The Report @ http://www.researchmoz.com/enquiry.php?type=sample&repid=238043
Apart from this, the Iron Deficiency Anemia Global Clinical Trials Review, H2, 2014 report also discusses the contribution of leading institutes and government bodies towards iron deficiency anemia clinical trials. The top institutes reviewed in the report are the University of Zurich, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Imperial College London, Stanford University, Soroka University Medical Center, HaEmek Medical Center, the University of Oxford, Swiss Federal Institute of Technology, The Hospital for Sick Children, and Wageningen University.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-997-4948
New York, NY (PRWEB) February 11, 2015
The testosterone attorneys (http://www.testosteronelawsuithub.com/testosterone-lawyer/) at Bernstein Liebhard LLP note the publication of a new report that questions the risks and benefits associated with prescription medications used to treat low testosterone in men. The article, which was published by U.S. News & World Report on February 6th, asserts that low testosterone is a far more complex condition than what is presented in much of the advertising used to drive sales of testosterone treatments. The report also pointed to a need for larger studies investigating the cardiovascular risks that may be associated with these drugs, as studies conducted thus far have produced conflicting findings.*
The publication of this report comes a little more than a year after the FDA launched a safety review to better assess the potential for heart complications related to the use of prescription testosterone treatments. It should also be noted that in September, a panel of agency advisors also recommended that the drugs be subjected to further research to better understand these risks, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices.** The Firm is representing men who allegedly suffered serious cardiovascular problems due to their use of low testosterone therapy, and continues to offer free case reviews to those who may have been harmed by prescription testosterone products.
Testosterone Heart Risks
The U.S. Food & Drug Administration announced its safety review of low testosterone treatments on January 31, 2014, after two studies tied the medications to an increased risk of heart attack, stroke and death in certain men. One of these studies reported that such treatments ware associated with a doubling of the heart attack risk among younger men with pre-existing heart problems, and in men over 65 regardless of their heart health. Another suggested an increased risk of heart attack, stroke and death among older men with pre-existing heart problems, the agency said.
In September, a panel of FDA advisors recommended that labeling on testosterone medications be adjusted to make clear their lack of proven effectiveness in treating low libido, fatigue, muscle loss and other symptoms men often experience as they age. Panelists also urged FDA to require manufacturers of testosterone replacement therapies to conduct large-scale studies of their cardiovascular side effects.**
Since the FDA launched its testosterone review last year, court records indicate that hundreds of testosterone lawsuits have been filed n a federal multidistrict litigation now underway in U.S. District Court, Northern District of Illinois. All of the claims pending in the proceeding were brought on behalf of men who allegedly experienced heart attacks, strokes, blood clots, and other cardiovascular problems due to their use of these medications. Among other things, these lawsuits accuse drug manufacturers of failing to adequately warn about the alleged association between testosterone replacement therapy and life-threatening heart complications. Plaintiffs further accuse the companies of concealing information about these side effects, and claim that misleading marketing tactics were used to promote the medications to patients who had no real medical need for testosterone treatment (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
Men who allegedly suffered serious cardiovascular events due to their use of prescription testosterone treatments may be entitled to compensation for their injury-related damages. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*health.usnews.com/health-news/patient-advice/articles/2015/02/06/treating-low-testosterone-weighing-risks-and-benefits, US News & World Report, February 6, 2015
**reuters.com/article/2014/09/17/us-usa-health-testosterone-idUSKBN0HC2C320140917, Reuters, September 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
Rochester, NY (PRWEB) February 11, 2015
Infected with the human papillomavirus (HPV)? The CBCD, which conducted two separate post-marketing clinical studies on the natural, antiviral formula of Novirin, recommends taking this effective HPV remedy to help the immune system target the latent HSV virus. – Greg Bennett, CBCD
Research shows that men who have sex with men (MSM) have higher rates of HPV infection in the mouth. This is important to note since oral infection with the high-risk HPV-16 is now known to be a cause of head and neck cancer. During the study it was found that oral high-risk HPV infection was significantly associated with a higher number of recent oral sex partners among MSM overall … (and) oral-anal contact in the previous six months was significantly associated with incident oral high-risk HPV infection. (1) For HIV infected men, the rates of HPV infection are even higher. A much higher prevalence of up to 25% has been reported among HIV-infected men who have sex with men (MSM). For these individuals, risk factors included a higher number of recent oral sex partners and both recent tobacco smoking and cannabis use were associated with incident oral high-risk HPV infection in multivariable analyses. (1) The CBCD recommends that HPV infected men take Novirin. This HPV remedy was shown to effectively reduce HPV symptoms in two separate post-marketing clinical studies that followed FDA guidelines.
Click to learn more about HPV symptoms.
The formula of Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Novirin formula is effective against the human papillomavirus (HPV). The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, individuals infected with HPVreported a safe decrease in their symptoms following treatment. (2) The study authors also wrote that, We observed a statistically significant decrease in the severity, duration, and frequency of symptoms. (2)
Novirin can be ordered on the product website here: http://www.novirin.com
Novirin is a natural antiviral dietary supplement. Its formula contains five natural ingredients: Selenium, Camellia Sinensis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin is the only natural antiviral product on the market with published clinical studies on its formula that supports its claims.
Men have weaker immune responses to the human papillomavirus (HPV) in comparison to women (See Urologic Oncology: Seminars and Original Investigations, from January 2014) (3). In other words, male immune systems are unable to control the latent HPV as efficiently. This is supported by serologic studies (studies of the blood) that find a higher prevalence of HPV antibodies (proteins used by the immune system) in women than in men across all ages (3).
New HPV infections are found in up to 39% of men every year (3). In men with healthy immune systems, HPV infections are cleared in 6 months or longer. However, in about 10% of all cases, when men have a weak immune system, HPV infections will persist. This can cause a variety of serious health problems. (See the CDC website last updated on July 25, 2013) (4).
For men, an HPV infection can lead to conditions, including genital warts, penile, anal, and oropharyngeal cancer (head and neck cancer) (4).
The CDC notes that HPV may be passed on during oral sex and genital-to-genital contact. HPV can be passed on between straight and same-sex partners-even when the infected partner has no signs or symptoms. (See the CDCs Website, last updated on February 5, 2013) (5).
What treatments are currently available against the HPV?
There are no drugs approved against the HPV. Current treatments include procedures, such as cryotherapy, conization, and the Loop Electrosurgical Excision Procedure (LEEP). These procedures use liquid nitrogen, a surgical knife (scalpel), a carbon dioxide (CO2) laser, or electrical current to remove the abnormal growths caused by the HPV. These growths include cells that harbor the active virus. The procedures do not target cells with the latent virus. Since they do not remove the latent virus, these procedures only produce a temporary remission. (5) In contrast, the formula of Novirin was designed to target the latent HPV.
Click to learn more about Novirin and HPV.
All orders of Novirin are completely confidential and no information is shared or sold to any third party. Privacy is assured.
(1) van Aar F, Mooij SH, van der Sande M, Meijer C, King AJ, Verhagen D, Heijman T, Coutinho RA, Schim van der Loeff MF. “Twelve-month incidence and clearance of oral HPV infection in HIV-negative and HIV-infected men who have sex with men: the H2M cohort study.” BMC Infect Dis. 2014 Dec 31;14(1):3845.
(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
(3) Amber Flaherty, M.D.a, Timothy Kim, M.D.b, Anna Giuliano, Ph.D.c, Anthony Magliocco, M.D., Ph.D.d, Tariq S. Hakky, M.D.b, Lance C. Pagliaro, M.D.e, Philippe E. Spiess, M.D., M.S. “Implications for human papillomavirus in penile cancer.” Urologic Oncology: Seminars and Original Investigations. Published in January 2014.
(4) CDC – Sexually Transmitted Diseases (STDs) – Genital HPV Infection – Fact Sheet. Last updated on July 25, 2013.
(5) CDC – Human Papillomavirus (HPV) – What is HPV? Last updated on February 5, 2013.
Rape as a Weapon of War, Made in the USA?
With that in mind it is worth returning to the assault on Libya and the allegation by Susan Rice, then US Ambassador to the UN, in April 2011, that the Libyan government was issuing Viagra to its troops, instructing them to use rape as a weapon of terror.
Read more on Center for Research on Globalization
Libya Lies – Rape as a Weapon of War – Made in the USA?
With that in mind it is worth returning to the assault on Libya and the allegation by Susan Rice, then US Ambassador to the UN, in April 2011, that the Libyan government was issuing Viagra to its troops, instructing them to use rape as a weapon of …
Read more on Dissident Voice
In the loop
Full of antioxidants and flavonoids, mamaki has been a treasured Hawaiian tea plant for decades. "This Hawaiian herbal tea has always traditionally been used for relaxation and stress reduction," says farmer and noted island musician George Kahumoku Jr …
Read more on Maui News
North York, Ontario (PRWEB) September 10, 2012
In the tradition of skilled researchers and developers that have discovered new products and remedies by accident, Nano Essentials is excited to announce their new Puralen herbal laxative. The result of a manufacturers accidental ingredient substitute for E-Drops, Puralen is an all-natural diuretic and stool softener that regulates colon and urinary tract health to treat constipation, clean the colon and act as a urinary tract antiseptic. Nano Essentials produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body.
While dedicated research in pursuit of a specific solution has brought about some of the worlds greatest products, happy accidents have played a highly significant role for an almost equal number of innovative solutions. From the microwave oven and Post-It Notes to Viagra and corn flakes, many of todays ubiquitous products are the result of happy accidents. Now, Puralen, the new herbal laxative from Nano Essentials joins that pantheon of groundbreaking solutions.
As a leading healthy nutraceuticals research and product development company, Nano Essentials has brought innovative all-natural products such as E-Drops Nano for urinary tract infections and cystitis to world markets. It was in the course of producing a new batch of their E-Drops Nano that the shipment of an incorrect manufacturing ingredient known as lecithin led to the discovery of Puralen. Lecithin is a naturally-occurring compound found in a variety of plant and animal tissues. Our 60 years of combined experience in research and development led us to experimentation with the different lecithin as a substitute ingredient in our very specific E-Drops Nano formulation, said Nano Essentials representative Vedran Hasanagic.
The Nano Essentials researchers thoroughly tested samples from the experimental batch in their laboratories and determined that the resultant product was not only safe, but had some interesting new medicinal properties. After internal testing with the president and select staff, they soon discovered that the alternate lecithin gave the drops an excellent and natural laxative property. After more testing on the all-natural experimental solution, we slightly modified it to enhance its bowel and digestive tract cleansing properties, said Hasanagic.
Dubbed Puralen, the digestive tract cleanser is an all-natural diuretic and stool softener that regulates colon and urinary tract health to treat constipation and clean the colon. Since it is an herbal solution based on the original E-Drops, it also acts as a urinary tract antiseptic.
What makes the new Puralen so innovative as an excellent digestive tract cleanser and herbal laxative is the fact that it causes no dependency after prolonged use and also has the added plus of providing pleasant breath to the user, said Hasanagic. As a research and development company using state-of-the-art nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals, Puralen fits perfectly with our mission of creating products that are all natural without the dangerous side effects of many pharmaceuticals.
For more information, please visit http://puralen.com/
Mukwonago, WI (PRWEB) December 12, 2014
Sherrie Palm, author of the award-winning book “Pelvic Organ Prolapse: The Silent Epidemic”, and the founder/executive director of APOPS, Association for Pelvic Organ Prolapse Support, a U.S.-based 501c3 nonprofit with international arms, is requesting contributions of any size to fund STIGMA*STRIDE Pennies for POP campaign.
After Palms book was named winner for Womens Health in the USA Book News National Best Books 2009 Awards, Palm founded the nonprofit organization to provide guidance and support to women suffering from pelvic organ prolapse, or POP.
POP is a little talked about female health condition that half the female population will experience throughout their lifetime. More than 300,000 surgeries are performed annually for the condition. A womans pelvic organs can shift out of normal positions from a variety of causes, such as childbirth, menopause, genetics, heavy lifting, chronic constipation, hysterectomy, or neuromuscular diseases. Women navigate embarrassing symptoms for years before being diagnosed and they suffer with pain, pressure, constipation, and incontinence, which impacts them physically, emotionally, socially, and sexually, as well as disrupts fitness and employment activities.
Pelvic organ prolapse has received little press or public acknowledgement, despite being on medical record for over 4,000 years. Palm calls POP the silent epidemic. Many women quietly suffer with POP due to embarrassment discussing their symptoms with health care practitioners.
Palms book “Pelvic Organ Prolapse: The Silent Epidemic” fills a void in womens health awareness. She defines POP and shares details about her own personal experience. Like most women, Palm had never heard about the condition until she was diagnosed and was in an advanced stage. Palms book explores pelvic organ prolapse from all angles, providing the information women need to recognize POP symptoms, understand POP causes, and navigate POP treatments.
Palm said, The time is here to generate viral awareness of pelvic organ prolapse and our efforts to generate change. We truly need everyones support. If each person who reads this donates $ 1 to help us make POP common knowledge for all women, and then forwards this information to family, friends, and social and employment networks asking them to join the campaign, well spawn viral energy and forward momentum. Pelvic organ prolapse disrupts the lives of women every day; millions suffer in silence with symptoms they dont understand. Im hopeful everyone will consider a $ 1 donation to help APOPS generate change; every voice matters!
Additional information about APOPS, pelvic organ prolapse, speaking presentations, or this book is available at:
http://www.pelvicorganprolapsesupport.org or http://sherriepalm.com.
This book and the charity campaign tell an important story that will help many women. We are proud to help spread the word, said Robert Fletcher, CEO of Strategic Book Publishing and Rights Agency.
“PELVIC ORGAN PROLAPSE: THE SILENT EPIDEMIC” (ISBN: 978-1-60693-965-9) is now available for $ 23.50 and can be ordered through the publishers website:
http://www.eloquentbooks.com/PelvicOrganProlapse.html, Amazon, or the website of Barnes & Noble.
WHOLESALERS: This book is distributed by Ingram Books and other wholesale distributors. Contact your representative with the ISBN for purchase. Wholesale purchase for retailers, universities, libraries, and other organizations is also available through the publisher; please email bookorder(at)sbpra(dot)net
About the Author: Sherrie Palm is the founder/executive director of APOPS/Association for Pelvic Organ Prolapse Support, author of Pelvic Organ Prolapse: The Silent Epidemic, a speaker and educator on the topic of pelvic organ prolapse, and an international grassroots POP health advocate. She dedicates her time to generating awareness of pelvic organ prolapse, and evolving guidance and support structures for women navigating POP.
Strategic Book Publishing and Rights Co, LLC